Evidence map›Paper›PMID 31061155›Full record

ArticleAntimicrobial agents and chemotherapy2019

Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications.

Masayuki Amano, Pedro Miguel Salcedo-Gómez, Ravikiran S Yedidi, Rui Zhao, Hironori Hayashi, Kazuya Hasegawa, Tomofumi Nakamura, Cuthbert D Martyr, Arun K Ghosh, Hiroaki Mitsuya

Open access · bronzeAbstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Frontiers in medical technology · 2020
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Masayuki AmanoDepartment of Infectious Diseases, Kumamoto University School of Medicine, Kumamoto, Japan.ORCID 0000-0003-0516-9502
Pedro Miguel Salcedo-GómezDepartment of Infectious Diseases, Kumamoto University School of Medicine, Kumamoto, Japan.
Ravikiran S YedidiExperimental Retrovirology Section, HIV and AIDS Malignancy Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0003-2755-1307
Rui ZhaoDepartment of Infectious Diseases, Kumamoto University School of Medicine, Kumamoto, Japan.
Hironori HayashiDepartment of Infectious Diseases, Kumamoto University School of Medicine, Kumamoto, Japan.
Kazuya HasegawaProtein Crystal Analysis Division, Japan Synchrotron Radiation Research Institute, Hyogo, Japan.
Tomofumi NakamuraDepartment of Infectious Diseases, Kumamoto University School of Medicine, Kumamoto, Japan.
Cuthbert D MartyrDepartment of Chemistry, Purdue University, West Lafayette, Indiana, USA.
Arun K GhoshDepartment of Chemistry, Purdue University, West Lafayette, Indiana, USA.
Hiroaki MitsuyaDepartment of Infectious Diseases, Kumamoto University School of Medicine, Kumamoto, Japan mitsuyah@nih.gov.ORCID 0000-0001-9274-3853
Kumamoto University · JPNational Institutes of Health · USPurdue University West Lafayette · USJapan Synchrotron Radiation Research Institute · JP

Funding

Design & Synthesis of Nonpeptide Protease InhibitorsR37GM053386 · NIGMS · PURDUE UNIVERSITY · PI GHOSH, ARUN K · 2011 to 2018
$3.9M
DESIGN AND SYNTHESIS OF NONPEPTIDE PROTEASE INHIBITORSR01GM053386 · NIGMS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI GHOSH, ARUN K · 1995 to 2010
$3.7M
Design & Synthesis of Nonpeptide Protease InhibitorsR37AI150466 · NIAID · PURDUE UNIVERSITY · PI GHOSH, ARUN K · 2019 to 2020
$969k
NIAID NIH HHS R37 AI150466NIGMS NIH HHS R01 GM053386NIGMS NIH HHS R37 GM053386
6 · The paper itself

Abstract

There is currently no specific therapeutics for the HIV-1-related central nervous system (CNS) complications. Here we report that three newly designed CNS-targeting HIV-1 protease inhibitors (PIs), GRL-083-13, GRL-084-13, and GRL-087-13, which contain a P1-3,5-

Indexed as

AnimalsAstrocytesBlood-Brain BarrierCatalytic DomainCentral Nervous System Viral DiseasesCrystallography, X-RayDrug Evaluation, PreclinicalDrug Resistance, ViralHIV-1HIV-2HIV InfectionsHIV ProteaseHIV Protease InhibitorsHumansRatsSulfonamidesHIV ProteaseHIV Protease Inhibitorsp16 protease, Human immunodeficiency virus 1Sulfonamidesdrug designdrug resistanceHIV-1HIV-1-associated neurocognitive disorders (HAND)protease inhibitor

Identifiers

PMID31061155
PMCPMC6591644
OpenAlexW2940726674

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.